NeurAxis (NRXS) Registration Filing summary

Company overview and business model

• Focuses on neuromodulation therapies for chronic and debilitating conditions in children and adults, with proprietary IB-Stim therapy based on Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.

• IB-Stim is FDA-cleared for functional abdominal pain associated with IBS in adolescents aged 11-18; additional pediatric clinical trials are ongoing.

• Incorporated in Indiana in 2012, re-incorporated in Delaware in 2022.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is $20,070,373, based on 6,980,227 shares and a $3.27 per share price as of November 14, 2024.

• Common stock is listed on NYSE American under the symbol “NRXS”; closing price was $2.64 on December 12, 2024.

Use of proceeds and capital allocation

• Net proceeds from company-offered securities will be used as set forth in the applicable prospectus supplement.

• No proceeds will be received from the sale of shares by selling stockholders; all such proceeds go directly to them.